Trabectedin/PLD Versus Continuation of Platinum-based Chemo-therapy in Patients With Disease Stabilization and no Symptom Benefit Under Platinum-based Chemotherapy for Recurrent Ovarian Cancer
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Doxorubicin liposomal (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Trabectedin (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 17 May 2019 Planned initiation date changed from 1 Feb 2019 to 22 May 2019.
- 17 May 2019 Status changed from not yet recruiting to recruiting.
- 08 Oct 2018 New trial record